A phase III, variable-dose titration followed by a randomized double-blind study of controlled-release OROS hydromorphone HCl (NMED-1077) compared to placebo in patients with chronic low back pain.

Trial Profile

A phase III, variable-dose titration followed by a randomized double-blind study of controlled-release OROS hydromorphone HCl (NMED-1077) compared to placebo in patients with chronic low back pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2012

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Neuromed Pharmaceuticals
  • Most Recent Events

    • 30 Apr 2010 Results published in Current Medical Research and Opinion.
    • 07 May 2009 Abstract presented at the 28th Annual Scientific Meeting of the American Pain Society (APS 2009).
    • 23 Mar 2009 Results reported by Neuromed Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top